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Summary. Factor replacement therapy for the
treatment of moderate to severe haemophilia A and B
can be complicated by the production of inhibitory
alloantibodies to factor VIII (FVIII) or factor IX.
Treatment with the nanofiltered anti-inhibitor
coagulant complex, Factor Eight Inhibitor Bypassing
Activity (FEIBA NF), is a key therapeutic option for
controlling acute haemorrhages in patients with high-
titre inhibitors or low-titre inhibitors refractory to
replacement therapy. Given the high risk for morbidity
and mortality in haemophilia patients with inhibitors
to FVIII or FIX, we conducted this Phase 3 prospective
study to evaluate whether prophylaxis with FEIBA NF
is a safe and effective treatment option. Over a 1-year
period, 17 subjects were treated prophylactically
(85  15 U kg1 every other day) while 19 subjects
were treated on demand. The median (IQR)
annualized bleeding rate (ABR) during prophylaxis
was 7.9 (8.1), compared to 28.7 (32.3) during on-
demand treatment, which amounts to a 72.5%
reduction and a statistically significant difference in
ABRs between arms (P = 0.0003). Three (17.6%)
subjects (ITT) on prophylaxis experienced no bleeding
episodes, whereas none treated on demand were
bleeding episode-free. Total utilization of FEIBA NF
for the treatment of bleeding episodes was significantly
higher during on-demand therapy than prophylaxis
(P = 0.0067). There were no differences in the rates of
related adverse events between arms. This study
demonstrates that FEIBA prophylaxis significantly
reduces all types of bleeding compared with on-
demand treatment, and the safety of prophylaxis is
comparable to that of on-demand treatment.
Keywords: FEIBA, haemophilia A/B, inhibitors, on-
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Introduction
The development of inhibitory alloantibodies to factor
VIII (FVIII) or factor IX (FIX) is the most serious and
challenging complication in haemophilia patients and
a major cause of morbidity and mortality as bleeds
are difficult to treat [1]. The presence of inhibitors
generally precludes the efficacious use of FVIII and
FIX replacement therapy, especially in patients with
high-responding and high-titre inhibitors, due to an
anamnestic response. Bleeding in patients with high-
or low-titre inhibitors refractory to replacement ther-
apy is treated with bypassing agents such as anti-
inhibitor coagulant complex (AICC) or activated
recombinant factor VII (rFVIIa).
Prophylactic therapy with FVIII in severe haemo-
philia A patients without inhibitors has been shown to
be highly beneficial in reducing bleeding episodes and
is considered standard of care [1–3]. Haemophilia A
and B patients with inhibitors may also benefit from
prophylactic therapy. Previous reports have shown
that prophylaxis with AICC, Factor Eight Inhibitor
Bypassing Activity (FEIBA) or rFVIIa reduces
morbidity and improves general health [4–9] and
health-related quality of life (HRQoL) [9–12]. A
recent prospective clinical study (PRO-FEIBA) with a
crossover design showed that FEIBA prophylaxis over
a 6-month period was associated with statistically
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significant reductions in all bleeding episodes (62%),
haemarthroses (61%), and target joints (72%) in hae-
mophilia A patients with high-titre inhibitors [13].
This study was designed to compare the efficacy,
safety and HRQoL of a prophylactic regimen of the
nanofiltered FEIBA NF, to an on-demand regimen
over a 12-month observation period.
Materials and methods
Patients
This study is registered at ClinicalTrials.gov
(NCT00851721). The protocol was approved by the
ethics committees of 17 participating institutions, and
written consent was obtained from patients before en-
rolment.
Patients were eligible for participation in the study
if they had haemophilia A or B with documented his-
tory of high-titre inhibitor (>5 BU) or low-titre inhibi-
tor (≤5 BU) refractory to increased dosing of either
FVIII or FIX for at least 12 months; were ≥4 and
≤65 years of age; were currently being treated on-
demand with bypassing agents; had ≥12 bleeding epi-
sodes in the previous 12 months; and a negative
human immunodeficiency virus (HIV) status, or if
positive, with a stable CD4 count. Patients were
excluded from the study if they had symptomatic liver
disease; had platelet count <100 000 mL1; were cur-
rently receiving ITI or prophylaxis; needed elective
surgery; needed alpha-interferon or protease inhibitor
use; or had previous thromboembolic events. Although
the study was open-label, a blocked randomization
scheme stratified by geography with 1:1 allocation to
each arm (12 months  14 days of prophylactic treat-
ment, or 12 months  14 days of on-demand treat-
ment) was generated. The use of a centralized and
blocked randomization scheme was to result in a bal-
anced number of subjects in each treatment arm.
Study design
This was a Phase 3, randomized, multicentre, open-
label, two-arm parallel study comparing prophylaxis
to an on-demand regimen. The prophylactic dose and
dosing regimen was based on a review of literature on
the use of FEIBA in the prevention of bleeding in
patients with haemophilia A with inhibitors to FVIII
[5–7]. The primary outcome was a reduction in the
annualized bleeding rate (ABR) among subjects on
prophylaxis as compared to those treated on-demand
over a period of 12 months  14 days. Secondary
outcome measures included the following: number of
bleeding episodes in joints, target joints (i.e. ankles,
knees, elbows and/or hips with ≥4 bleeds over
6 months), and other anatomical locations; occurrence
of new target joints; pain, joint range of motion
(ROM) and haemostatic efficacy; total FEIBA NF uti-
lization and the number of infusions required to treat
a bleeding episode; pharmacoeconomics and HRQoL;
and safety.
Treatments
Prophylaxis dosing was 85 15 U kg1 by i.v. bolus
infusion every other day. On-demand dosing as well
as dosing for the treatment of bleeding while on pro-
phylaxis was dependent upon the type of bleeding and
was at the discretion of the investigator (as described
in the Supporting Information).
Clinical, pharmacoeconomic, and HRQoL
assessments
Descriptions of bleeding episodes (including aetiology,
severity and anatomical site), pharmacoeconomic data,
adverse events (AEs) and FEIBA NF infusion details
were recorded in subject diaries and verified by the
investigator. Each episode may have included more
than one joint or non-joint anatomical site. Haemo-
static efficacy was assessed by the number of infusions
used to treat each episode and by the subject’s rating
based on a 4-point ordinal scale (excellent, good, fair,
or none; see full descriptions in Supporting Informa-
tion). Joint ROM measurements and clinical chemistry
testing were performed at screening, 6 months and
termination.
Factor VIII and FIX inhibitor assessments (Nijmegen
assay modification of the Bethesda assay [14]), com-
plete blood count and coagulation tests were per-
formed every 3 months; clinically significant abnormal
values were reported as AEs. Viral serology testing for
HIV type 1 and 2, hepatitis A virus (HAV), hepatitis
B virus (HBV), hepatitis C virus (HCV) and parvovi-
rus B19 (B19V) was performed at baseline and termi-
nation.
Health-related quality of life was assessed at screen-
ing, 6 months and at termination using the EQ-5D
[15], Haem-A-QoL [16], Haemo-QoL [17], and visual
analogue scale (VAS) for general pain assessment
[18,19].
Statistical analyses
The sample size calculation assumed that 30 subjects
(15 per arm) would provide greater than 80% power
to detect a reduction of 50% in ABRs during prophy-
laxis compared with on-demand therapy. To account
for a 12% subject dropout, at least 34 subjects were
planned for randomization.
Efficacy analyses were performed with two analysis
sets: intent-to-treat (ITT), which included all subjects
who were randomized (used for primary analysis);
and per-protocol (PP), which included all subjects
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who completed the treatment period with ≥80%
adherence to dose and frequency of dose. ABRs were
transformed using the square root of the number of
bleeding episodes observed (X = bleeds per year),
X0 = (X + 0.5) to stabilize the variance and align the
sample distribution with the assumption of normality
inherent in using the t-test. The difference in mean
transformed ABRs was used to perform statistical tests
and to generate P–values (two-sample, two-sided t-test
with a significance level of 5%). To further assess dif-
ferences in ABRs between regimens, a negative bino-
mial mixed model was used to evaluate the number of
bleeding episodes as the dependent variable with the
logarithm of time as the offset variable and regimen
as the independent variable. A repeated effect over
time was included because each subject contributed
multiple observations during their treatment period.
Secondary efficacy outcome measures were, for the
most part, descriptively compared between arms for
all subjects with at least one treated bleeding episode.
In addition, HRQoL and general pain assessments and
pharmacoeconomic parameters were descriptively
compared between arms for all randomized subjects
with any available assessments. Safety assessments
were descriptively compared between arms for all sub-
jects who received at least one infusion of FEIBA NF.
Results
Subjects
A total of 36 subjects were randomized and treated
with FEIBA NF (17 in the prophylaxis arm and 19 in
the on-demand arm) and they comprised the efficacy
and HRQoL ITT and safety analysis sets. For details
on subject disposition, refer to Fig. 1.
All treated subjects were male and their median age
was 23.5 years (range: 7–56). Overall demographic
and baseline characteristics were similar between arms
(Table 1).
Median (minimum–maximum) weight-adjusted dose
per infusion was 81 U kg1 (72–91) in the prophy-
laxis arm and 70 U kg1 (50–106) in the on-demand
arm, and the dose for treating breakthrough bleeding
during prophylaxis was 82 U kg1 (48–97). The med-
ian (minimum–maximum) total number of units
administered per subject was 904 354 U (35 432–
1 384 714) in the prophylaxis arm and 305 740 U
(46 640–714 913) in the on-demand arm. Thus, total
product usage in the prophylaxis arm was 3.0-fold
greater than usage in the on-demand arm.
Primary outcome
During the 12-month study period, 196 bleeding epi-
sodes occurred during prophylaxis and 629 occurred
during on-demand therapy. Three of the 17 (17.6%)
prophylaxis subjects (ITT analysis set) were bleeding
episode-free during the study; of these, two completed
the study (12 months) and one was in study for
2.5 weeks. None of the 19 on-demand subjects were
bleeding episode-free. The median (IQR) ABR for the
on-demand arm was 28.7 (32.3) compared to 7.9
(8.1) for the prophylaxis arm, which amounts to a
72.5% reduction and a statistically significant differ-
ence in ABRs between arms (P = 0.0003, see Fig. 2).
These results support the primary objective of this
study.
To further confirm these results, an evaluation of the
influence of treatment regimen on the number of bleed-
ing episodes over time revealed an increased incidence
of bleeding associated with the on-demand regimen
(negative binomial mixed effects model; coeffi-
cient = 0.9993, standard error = 0.2945, P = 0.0007).
When analysed by bleeding aetiology and/or type,
statistically significant differences between on-demand
and prophylaxis regimens were observed for spontane-
ous (P = 0.0008), traumatic (P = 0.0199), joint
(P = 0.0006), and non-joint (P = 0.0227) bleeding
episodes, as well as spontaneous-joint (P = 0.0013),
spontaneous-non-joint (P = 0.0030) and traumatic-
joint bleeding episodes (P = 0.0254). Median (IQR)
ABRs and relative per cent reductions in ABRs for the
prophylaxis arm compared with the on-demand arm
are shown in Fig. 2.
In the prophylaxis arm, median (IQR) ABRs were
higher during the first 6 months of treatment than the
last 6 months of treatment (8.0 [13.5] vs. 5.9 [19.1];
not significant).
A post hoc analysis compared the number of bleeding
episodes in subjects who reported ≥12 historical
episodes during a 12-month, prestudy period of
on-demand therapy with bypassing agents with the
number of episodes during the 12-month study period.
A ≥50% reduction in the number of bleeding episodes
was observed in 12 of 16 prophylaxis subjects vs. 2 of
19 on-demand subjects, which is consistent with the
PRO-FEIBA study’s definition of a good responder
[13]. The median per cent change for all bleeds between
arms was statistically significant in favour of prophy-
lactic therapy (14.1% vs. 64.4%, P = 0.0001).
Secondary outcomes
Occurrence of new target joints. A new target joint
was defined as an ankle, knee, elbow or hip joint in
which ≥4 bleeding episodes occurred in the same joint
within a 6 month period during the study and was not
a target joint at study initiation. The occurrence of
new target joints was substantially lower in the pro-
phylaxis arm than in the on-demand arm; 7 new target
joints in 5/17 [29.4%] prophylaxis subjects [range per
subject: 1–2] vs. 23 new target joints in 11/19 [57.9%]
on-demand subjects [range per subject: 1–6] (Fig. 3).
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Incidence of bleeding episodes by site. The majority
of bleeding episodes occurred in joints (572 during
on-demand therapy and 171 during prophylaxis) vs.
other non-joint anatomical locations (57 during on-
demand therapy and 25 during prophylaxis). In the
on-demand arm, 243/572 (42.48%) joint bleeding epi-
sodes occurred in new target joints, while in the pro-
phylaxis arm, 81/171 (47.37%) occurred in existing
target joints. The median (IQR) ABR for new target
joints was higher in the on-demand arm (5.9 [12.9])
than in the prophylaxis arm (0 [4.1]); this difference
was statistically significant (P = 0.0271).
Treatment of bleeding. The proportions of bleeding
episodes treated with 1–2, 3, or ≥4 infusions were
similar between arms, as were the proportion of treat-
ments rated excellent/good, fair, and none. The major-
ity (78.5%) of all bleeding episodes were treated with
1–2 infusions and the majority (87.1%) of treatments
were rated by the subject as having excellent or good
haemostatic efficacy at the 24  1 h post infusion
(Table 2). The median (IQR) total utilization of FEI-
BA NF to treat bleeding episodes was significantly
higher during on-demand therapy (4049.7 [5083.9]
U kg1) than prophylaxis (1524.9 [2590.2] U kg1)
(P = 0.0067).
HRQoL and ROM. There were no statistically signif-
icant differences between the prophylaxis and on-
demand arms for the HRQoL and ROM results when
controlling for multiple comparisons; the study was
not statistically powered to show a difference for these
outcome measures due to the small sample size and
limited observation period offered by the 12-month
study (ROM). Subjects in the prophylaxis arm
reported mean (SD) improvement in HRQoL as
Assessed for Eligibility
(N = 52)
Discontinued (N = 16)
- Eligibility criteria (N = 10)
- Subject withdrew consent (N = 3)
- Sponsor/investigator decision (N = 3)
Randomized and Treated (N = 36)
Safety Analysis Set 
On-Demand (N = 19) Prophylaxis (N = 17)
Discontinued (N = 1)
- AE of hypersensitivity
Discontinued (N = 2)
- SAE of arteriosclerosis and
hypertensive cardiovascular 
disease (N = 1)
- Planned surgery (N = 1)
Total Completed (N = 33)
On-Demand (N = 17)
Prophylaxis (N = 16)
Fig. 1. Subject disposition flow diagram.
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measured by EQ-5D Index and EQ-VAS scores (0.08
[0.26] and 15.7 [18.68] respectively) at termina-
tion, which can be considered clinically meaningful
(minimally important difference threshold = 0.07
points and 7.0 points respectively [20,21]), while sub-
jects in the on-demand arm did not (0.01 [0.25]
and 5.8 [21.30] respectively). Compared to on-
demand, prophylaxis subjects had greater mean (SD)
improvement in Haem-A-QoL total score (9.5
[12.77] vs. 6.1 [15.41]) and in 8 of 10 Haem-A-
QoL domains, greater mean (SD) reduction in gen-
eral pain scores (23.2 [46.61] vs. 5 [28.70], a 3.6-
fold reduction), and lower mean (SD) number of
days lost from school/work due to bleeding episodes
(8.8 [14.42], vs. 16.4 [25.76]). The number of hos-
pitalizations for bleeding episodes was similar between
arms. ROM in the three key joints (ankles, knees and
elbows) was maintained or improved over the course
of the study in both arms.
Safety. Among the 36 treated subjects, no thrombo-
embolic events or major safety issues were identified.
Furthermore, an evaluation of laboratory markers of
thrombogenicity did not reveal any apparent trends
over time.
Twenty-three (23; 63.9%) subjects reported a total
of 104 AEs, of which 74 (71.2%) in 17 (47.2%) sub-
jects were non-serious AEs and 30 (28.8%) in 13
(36.1%) subjects were serious adverse events (SAEs;
see Table 3). One fatal SAE attributed to atheroscle-
rotic and hypertensive cardiovascular disease was
reported in a 51-year-old on-demand subject after
5 months in the study. This event was considered unli-
kely related to FEIBA NF due to the absence of tem-
poral association (at least 11 days between treatment
and last known contact before the reported death)
with product exposure. One subject discontinued the
study due to hypersensitivity reaction considered pos-
sibly related to FEIBA NF. The median (IQR) rates of
related AEs per year were similar in the on-demand
(0.000 [0.000]) and the prophylaxis (0.000 [0.979])
arm.
Of the subjects evaluated for changes in inhibitor
classification (i.e. from low to high titre or from high
to low titre) at screening and termination, the major-
ity (23/31) of haemophilia A subjects and 2/3 haemo-
philia B subjects did not change their classification.
One on-demand subject and two prophylaxis subjects
had high-titre inhibitors at screening that changed to
low-titre inhibitors by termination. Two subjects in
the on-demand arm (2.3–6.1 BU and 4.9–79.6 BU)
and one in the prophylaxis arm (3.7–9.5 BU) had a
rise in inhibitor levels from low to high titre. In three
subjects, two haemophilia A and one haemophilia B
subject, a low-titre inhibitor at screening was no
longer detectable at study termination.
An unexpected finding in this study was the HBsAb
positive results in seven subjects at termination. In
three of these subjects, there was a history of HBV
vaccination or prior HBV infection. Of the remaining
four subjects, two reverted back to an HBsAb negative
titre 2 months after the study completion. All four
subjects were tested for HBcAb, HBsAg and HBV
DNA by PCR and were found to be negative, indicat-
ing an absence of HBV infection. On the basis of
extensive analysis of the immunoglobulin content of
FEIBA NF, the titres of HBsAb in the retention
plasma pools of lots tested and the detection level of
the HBsAb assay, we believe that passive transfer of
HBsAb from FEIBA NF provides a highly plausible
explanation for the positive serology in some subjects.
No subject manifested signs of an active HBV infec-
tion.
Discussion
The prophylactic regimen of FEIBA NF in haemo-
philia A and B subjects with inhibitors yielded a statis-
tically significant and clinically relevant reduction in
the number of all bleeding episodes when compared in
a prospective manner to the on-demand regimen. In
particular, the data showed reductions in the rate of
bleeding episodes of all aetiologies and types during
prophylaxis vs. on-demand therapy, with the excep-
tion of traumatic non-joint bleeding episodes. A sec-
ondary analysis (negative binomial mixed effects
model) further confirmed an increased incidence of
bleeding was associated with the on-demand regimen.
Table 1. Subject characteristics.
N (%) of Treated Subjects
All
(36 subjects)
On-demand
(19 subjects)
Prophylaxis
(17 subjects)
Age
≥7 and <12 years 5 (13.9) 2 (10.5) 3 (17.6)
≥12 and <16 years 4 (11.1) 2 (10.5) 2 (11.8)
≥16 years of age 27 (75.0) 15 (78.9) 12 (70.6)
Race
White 29 (80.6) 14 (73.7) 15 (88.2)
Asian 3 (8.3) 2 (10.5) 1 (5.9)
Black or
African American
2 (5.6) 2 (10.5) 0 (0.0)
Other 2 (5.6) 1 (5.3) 1 (5.9)
Ethnicity
Non-hispanic or
non-latino
32 (88.9) 17 (89.5) 15 (88.2)
Hispanic or Latino 4 (11.1) 2 (10.5) 2 (11.8)
Haemophilia type
Haemophilia A 33 (91.7) 17 (89.5) 16 (94.1)
Haemophilia B 3 (8.3) 2 (10.5) 1 (5.9)
Severity of haemophilia
Moderate 3 (8.3) 2 (10.5) 1 (5.9)
Severe 33 (91.7) 17 (89.5) 16 (94.1)
Number of target joints
0 9 (25.0) 5 (26.3) 4 (23.5)
1 14 (38.9) 8 (42.1) 6 (35.3)
2–3 8 (22.2) 4 (21.1) 4 (23.5)
≥4 5 (13.9) 2 (10.5) 3 (17.6)
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Moreover, median (IQR) ABRs in the prophylaxis
arm were higher during the first 6 months of treat-
ment than the last 6 months of treatment (8.0 [13.5]
vs. 5.9 [19.1]), suggesting that longer duration of pro-
phylaxis may further reduce bleeding in some patients.
Overall, our primary outcome data complements
the results of the recent prospective PRO-FEIBA
study. However, the shorter duration of observation
in PRO-FEIBA may not have accounted for possible
seasonal effects (6 months vs. 12 months), showing a
smaller reduction in the number of all bleeding epi-
sodes (62% vs. 72.5%) during prophylaxis. While the
demographic characteristics of respective study popu-
lations were similar, efficacy results presented here
should be interpreted in the light of differences in
study designs (i.e. parallel vs. crossover). Interestingly,
the interval between prophylactic dosing in both stud-
ies (every 48–72 h) exceeded the pharmacodynamic
5.9
23
0
7
0
5
10
15
20
25
Median ABRs of new target joint
bleeding episodes
Number of new target joints
On-demand Prophylaxis
P = 0.0271
Fig. 3. New target joints and associated bleeding episodes.
Table 2. Haemostatic efficacy of treatment.
All On-demand Prophylaxis
Number of infusions to treat bleeding episodes (%)
1–2 78.5 78.0 80.3
3 9.4 10.0 7.5
≥4 12.1 12.0 12.1
Bleeding episode efficacy ratings at 24  1 h (%)
Excellent/good 87.1 90.2 75.7
Fair 6.0 5.8 6.9
None 0.1 0.2 0
Not done 6.5 3.9 16.2
Not available 0.3 0 1.2
h, hour(s).
0
5
10
15
20
25
30
A
BR
Bleeding eƟology and/or Type
On-demand
Prophylaxis
(b)
All Spontaneous Traumatic Joint Non-Joint Spontaneous 
Joint
Spontaneous 
Non-Joint
Traumatic 
Joint
Traumatic 
Non-Joint
On-demand 28.7 (32.3) 18.9 (32.6) 4.7 (8.7) 22.9 (32.8) 2.9 (4.0) 16.6 (30.9) 1.0 (2.0) 4.0 (6.1) 0 (1.9)
Prophylaxis 7.9 (8.1) 5.6 (5.1) 2.5 (3.1) 6.0 (7.1) 0.5 (2.0) 4.5 (5.1) 0 (1.0) 1.0 (3.1) 0 (1.0)
P-valuea 0.0003 0.0008 0.0199 0.0006 0.0227 0.0013 0.0030 0.0254 Not 
Significant
% Reduction 72.5 70.5 47.3 73.8 83.4 73.0 100.0 74.8 ND
a Two-sample two-sided t-test was used at with a significance level of 5%, using the difference in mean transformed ABR.
(a)
Fig. 2. Comparison of ABRs (ITT analysis set). (a) Median ABRs during treatment regimens. (b) Median (IQR) ABRs and per cent reductions during Pro-
phylaxis vs. On-demand therapies.
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half-life of FEIBA as determined by thrombin
generation assays (approximately 6 h) [22], and both
prophylactic regimens were shown to be effective.
As expected for subjects in this study, the majority
(90%) of bleeding episodes occurred in joints. Of the
haemarthroses that occurred in subjects treated pro-
phylactically, most were in existing target joints, while
the majority of those in subjects treated on-demand
were in new target joints. Thus, a statistically signifi-
cant difference in the ABR in new target joints was
observed between arms. Importantly, the development
of new target joints was less common in the prophy-
laxis arm than on-demand arm. Therefore, we hypoth-
esize that prophylaxis could prevent repeated joint
bleeding and the development of new target joints,
which is particularly promising for inhibitor patients
with absent or minimal joint damage who start long-
term primary prophylaxis at an early age [7,23,24].
The haemostatic efficacy of the treatment of bleed-
ing episodes was similar among regimens, which is
consistent with the results of FVIII usage in haemo-
philia A subjects without inhibitors [25–27].
Total FEIBA usage during the every-other-day pro-
phylaxis regimen was comparable to usage during the
thrice-weekly regimen of the PRO-FEIBA study in
haemophilia A subjects with FVIII inhibitors (3.0- vs.
2.4-fold greater than on-demand usage) [13], and even
to prophylactic FVIII usage in haemophilia A subjects
without inhibitors (2.4- to 3.1-fold greater than on-
demand usage) [28]. The increased usage costs associ-
ated with FEIBA NF prophylaxis should be weighed
against the benefits of this treatment option as
reported in this study and the literature (reduction in
bleeding episodes, morbidity, improvement in general
health and HRQoL) [4–7,10–13].
While this study was not powered to show statisti-
cally significant differences in HRQoL and ROM, a
greater tendency for improvement was noted in sub-
jects during prophylaxis with respect to: EQ-5D Index
and VAS scores; Haem-A-QoL total score; scores for
8 of 10 Haem-A-QoL domains; general pain scores;
and number of days lost from work or school due to
bleeding episodes. Furthermore, ROM for the three
key joints (ankles, knees and elbows) was maintained
or improved over the course of the study in both
arms. This study was not designed to address long-
term effects of prophylaxis on the progression of joint
disease.
FEIBA has two viral inactivation steps in its manu-
facturing process, minimizing any potential risks of
hepatitis viral transmission. Detailed monitoring of
HBV serology and PCR testing implemented through-
out this study detected four HBsAb positive cases,
which were attributed to passive transfer of antibodies
from plasma used in the manufacture of FEIBA. This
interpretation is fully consistent with the current
extensive HBV vaccination history of plasma donors.
The passive transfer of these antibodies is transitory
(which can explain the reversion to HBsAb negative
titre in two of four subjects) and is based on the half-
life of IgG and continued administration of high doses
of FEIBA NF or other plasma products. These four
cases represent transient hepatitis B surface antibody
seroconversion and not viral transmission (active HBV
infection).
There were also no thromboembolic events reported
and no notable trends in thrombotic markers observed
during the study further supporting the safety profile
of FEIBA NF in terms of potential viral infections and
thromboses.
Conclusion
A prophylactic regimen with FEIBA NF was shown to
be effective and safe in the reduction in bleeding,
including bleeding in joints and target joints and devel-
opment of new target joints in patients with persistent
high-titre inhibitors and low-titre inhibitors refractory
to FVIII or FIX treatment. Taken together, this study
Table 3. Serious adverse events and related non-serious adverse events.
Preferred term
On-demand
(N = 19)
Prophylaxis
(N = 17)
All
(N = 36)
Number
of AEs
N
(%)*
Number
of AEs
N
(%)* N (%)†
Serious adverse events
Abdominal wall
haematoma
0 0 (0.0) 1 1 (5.9) 1 (2.8)
Cholecystitis
acute
1 1 (5.3) 0 0 (0.0) 1 (2.8)
Haematoma
infection
1 1 (5.3) 0 0 (0.0) 1 (2.8)
Femoral neck
fracture
1 1 (5.3) 0 0 (0.0) 1 (2.8)
HBsAb positive 1‡ 1 (5.3) 4§ 4 (23.5) 5 (13.9)
Arthropathy 1 1 (5.3) 0 0 (0.0) 1 (2.8)
Haemarthrosis 3 1 (5.3) 8 2 (11.8) 3 (8.3)
Muscle
haemorrhage
0 0 (0.0) 1 1 (5.9) 1 (2.8)
Haematuria 1 1 (5.3) 0 0 (0.0) 1 (2.8)
Epistaxis 1 1 (5.3) 0 0 (0.0) 1 (2.8)
Catheter removal 1 1 (5.3) 0 0 (0.0) 1 (2.8)
Arteriosclerosis 1 1 (5.3) 0 0 (0.0) 1 (2.8)
Haematoma 0 0 (0.0) 2 1 (5.9) 1 (2.8)
Haemorrhage 1 1 (5.3) 0 0 (0.0) 1 (2.8)
Hypertensive
crisis
1 1 (5.3) 0 0 (0.0) 1 (2.8)
Related non-serious adverse events
Headache 20 1 (5.3) 0 0 (0.0) 1 (2.8)
Dizziness 1 1 (5.3) 0 0 (0.0) 1 (2.8)
Hypersensitivity 0 0 (0.0) 1 1 (5.9) 1 (2.8)
Hypotension 0 0 (0.0) 1 1 (5.9) 1 (2.8)
Rash 0 0 (0.0) 1 1 (5.9) 1 (2.8)
AE, adverse event; N (%), number of subjects (% of subjects); HBsAb,
hepatitis B surface antibody.
*Per cent relative to total number of subjects exposed to FEIBA NF
within each arm.
†Per cent relative to total number of subjects exposed to FEIBA NF.
‡This SAE was considered related to administration of FEIBA NF.
§Three of these four SAEs were considered related to administration of
FEIBA NF (two by investigators and one by sponsor).
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and that of Leissinger et al. [13] provide basis for opti-
mism that the therapy of patients with inhibitors can
be significantly improved with prophylaxis leading to
better orthopaedic and overall outcomes.
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